Share Price and Basic Stock Data
Last Updated: February 6, 2026, 8:50 pm
| PEG Ratio | -35.88 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Healthcare Global Enterprises Ltd (HCG) operates within the Hospitals & Medical Services industry, focusing on providing comprehensive healthcare solutions. As of the latest reporting, the company’s stock price stood at ₹588 with a market capitalization of ₹8,290 Cr. Sales have shown a consistent upward trend, increasing from ₹1,691 Cr in FY 2023 to ₹1,908 Cr in FY 2024, and projected at ₹2,218 Cr in FY 2025. Quarterly sales figures have also reflected this growth, with ₹487 Cr recorded in September 2023, up from ₹442 Cr in March 2023. This growth trajectory is notable within the healthcare sector, where average revenue growth rates can vary significantly. HCG’s ability to enhance its service offerings and expand its patient base has likely contributed to this positive trend, aligning with the rising demand for healthcare services across India.
Profitability and Efficiency Metrics
HCG’s profitability metrics indicate a mixed performance, with an operating profit margin (OPM) of 19% as of recent reports, which is competitive against industry averages. The company recorded a net profit of ₹41 Cr for the period, translating into a net profit margin of approximately 2.16% for FY 2025. However, the price-to-earnings (P/E) ratio stood at a high 234, suggesting that the stock may be overvalued relative to earnings. Return on equity (ROE) was reported at 5.14%, while return on capital employed (ROCE) was at 8.56%, both of which are on the lower side compared to industry standards. Efficiency ratios also reveal a cash conversion cycle (CCC) of -111 days, indicating strong liquidity and operational efficiency, as the company effectively manages its receivables and payables.
Balance Sheet Strength and Financial Ratios
The balance sheet of HCG reflects a total borrowing of ₹1,768 Cr against reserves of ₹780 Cr, indicating a reliance on debt financing. The debt-to-equity ratio stood at 1.09, suggesting a moderate level of financial leverage, which can pose risks if cash flows do not support interest obligations. The interest coverage ratio (ICR) was recorded at 2.73, reflecting the company’s ability to meet its interest expenses. The book value per share was reported at ₹66.16, and the price-to-book value (P/BV) ratio was high at 8.13x, signaling that the market values the company significantly higher than its book assets. While the total assets reached ₹3,540 Cr, the current ratio stood at 0.80, which is below the ideal benchmark of 1, indicating potential liquidity challenges in meeting short-term obligations.
Shareholding Pattern and Investor Confidence
Healthcare Global’s shareholding structure shows a significant level of promoter ownership at 63.78%, which indicates a strong commitment from the founding members. Foreign institutional investors (FIIs) hold 3.59%, while domestic institutional investors (DIIs) have increased their stake to 18.36%. The public shareholding stands at 14.28%, with a total of 46,970 shareholders. The gradual decline in promoter shareholding from 71.39% in December 2022 to the current level may raise questions regarding long-term commitment, yet it could also suggest strategic moves to attract institutional investors. The increase in DIIs’ holdings reflects growing confidence among domestic institutional players, which may enhance stability and support for the stock price in the long run.
Outlook, Risks, and Final Insight
Looking forward, HCG is well-positioned to capitalize on the expanding healthcare market in India, driven by rising healthcare demand and increasing health awareness. However, the high P/E ratio and low ROE present challenges that could deter potential investors. Risks include reliance on debt, which could impact financial stability if operational cash flows do not improve. Further, regulatory changes and increasing competition in the healthcare sector may pose additional challenges. The company’s focus on expanding its service offerings and improving operational efficiency will be critical in navigating these risks. Should HCG successfully enhance its profitability metrics and manage its debt levels, it could significantly improve investor sentiment and market performance.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| NG Industries Ltd | 48.9 Cr. | 146 | 187/120 | 9.98 | 117 | 2.40 % | 23.6 % | 20.7 % | 10.0 |
| Global Longlife Hospital and Research Ltd | 14.9 Cr. | 14.2 | 33.0/13.1 | 24.3 | 0.00 % | 13.7 % | 17.7 % | 10.0 | |
| Gian Lifecare Ltd | 10.4 Cr. | 10.1 | 20.5/7.08 | 18.7 | 0.00 % | 3.00 % | 0.81 % | 10.0 | |
| Fortis Malar Hospitals Ltd | 104 Cr. | 55.2 | 98.7/52.2 | 22.8 | 18.3 | 0.00 % | 0.83 % | 0.56 % | 10.0 |
| Family Care Hospitals Ltd | 19.2 Cr. | 3.55 | 6.30/3.28 | 1.51 | 0.00 % | 79.2 % | 85.5 % | 10.0 | |
| Industry Average | 25,485.00 Cr | 681.69 | 87.63 | 92.86 | 0.35% | 15.48% | 14.81% | 9.04 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 420 | 425 | 442 | 461 | 487 | 470 | 495 | 526 | 554 | 559 | 585 | 613 | 647 |
| Expenses | 345 | 349 | 365 | 386 | 402 | 391 | 403 | 435 | 451 | 470 | 480 | 505 | 524 |
| Operating Profit | 75 | 76 | 76 | 74 | 85 | 79 | 92 | 91 | 102 | 88 | 106 | 108 | 123 |
| OPM % | 18% | 18% | 17% | 16% | 17% | 17% | 19% | 17% | 18% | 16% | 18% | 18% | 19% |
| Other Income | 2 | 4 | 5 | 3 | 3 | 6 | 9 | 9 | 11 | 6 | 10 | 8 | 3 |
| Interest | 26 | 27 | 26 | 26 | 27 | 29 | 27 | 34 | 36 | 41 | 44 | 45 | 44 |
| Depreciation | 41 | 41 | 42 | 41 | 43 | 44 | 46 | 47 | 50 | 57 | 58 | 58 | 63 |
| Profit before tax | 10 | 11 | 13 | 11 | 18 | 11 | 28 | 19 | 28 | -3 | 14 | 12 | 20 |
| Tax % | 47% | 63% | 57% | 65% | 40% | 69% | 17% | 28% | 25% | -335% | 50% | 50% | -4% |
| Net Profit | 5 | 4 | 6 | 4 | 11 | 3 | 23 | 14 | 21 | 8 | 7 | 6 | 21 |
| EPS in Rs | 0.53 | 0.54 | 0.60 | 0.55 | 0.97 | 0.41 | 1.53 | 0.87 | 1.29 | 0.50 | 0.53 | 0.34 | 1.15 |
Last Updated: January 1, 2026, 12:16 pm
Below is a detailed analysis of the quarterly data for Healthcare Global Enterprises Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 647.00 Cr.. The value appears strong and on an upward trend. It has increased from 613.00 Cr. (Jun 2025) to 647.00 Cr., marking an increase of 34.00 Cr..
- For Expenses, as of Sep 2025, the value is 524.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 505.00 Cr. (Jun 2025) to 524.00 Cr., marking an increase of 19.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 123.00 Cr.. The value appears strong and on an upward trend. It has increased from 108.00 Cr. (Jun 2025) to 123.00 Cr., marking an increase of 15.00 Cr..
- For OPM %, as of Sep 2025, the value is 19.00%. The value appears strong and on an upward trend. It has increased from 18.00% (Jun 2025) to 19.00%, marking an increase of 1.00%.
- For Other Income, as of Sep 2025, the value is 3.00 Cr.. The value appears to be declining and may need further review. It has decreased from 8.00 Cr. (Jun 2025) to 3.00 Cr., marking a decrease of 5.00 Cr..
- For Interest, as of Sep 2025, the value is 44.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 45.00 Cr. (Jun 2025) to 44.00 Cr., marking a decrease of 1.00 Cr..
- For Depreciation, as of Sep 2025, the value is 63.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 58.00 Cr. (Jun 2025) to 63.00 Cr., marking an increase of 5.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 20.00 Cr.. The value appears strong and on an upward trend. It has increased from 12.00 Cr. (Jun 2025) to 20.00 Cr., marking an increase of 8.00 Cr..
- For Tax %, as of Sep 2025, the value is -4.00%. The value appears to be improving (decreasing) as expected. It has decreased from 50.00% (Jun 2025) to -4.00%, marking a decrease of 54.00%.
- For Net Profit, as of Sep 2025, the value is 21.00 Cr.. The value appears strong and on an upward trend. It has increased from 6.00 Cr. (Jun 2025) to 21.00 Cr., marking an increase of 15.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 1.15. The value appears strong and on an upward trend. It has increased from 0.34 (Jun 2025) to 1.15, marking an increase of 0.81.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:16 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 451 | 519 | 584 | 700 | 829 | 976 | 1,092 | 1,009 | 1,395 | 1,691 | 1,908 | 2,218 | 2,404 |
| Expenses | 413 | 443 | 499 | 595 | 713 | 864 | 936 | 887 | 1,161 | 1,394 | 1,581 | 1,835 | 1,979 |
| Operating Profit | 38 | 76 | 85 | 105 | 116 | 112 | 157 | 122 | 234 | 297 | 327 | 384 | 425 |
| OPM % | 9% | 15% | 15% | 15% | 14% | 11% | 14% | 12% | 17% | 18% | 17% | 17% | 18% |
| Other Income | 3 | 0 | -2 | 10 | 25 | 10 | 10 | -72 | 110 | 15 | 24 | 39 | 26 |
| Interest | 32 | 34 | 38 | 23 | 42 | 70 | 138 | 119 | 98 | 104 | 109 | 155 | 174 |
| Depreciation | 36 | 39 | 44 | 57 | 71 | 85 | 148 | 159 | 158 | 163 | 174 | 211 | 235 |
| Profit before tax | -27 | 3 | 0 | 35 | 27 | -33 | -119 | -229 | 88 | 45 | 68 | 57 | 42 |
| Tax % | 20% | -56% | -730% | 34% | 38% | -7% | 5% | -3% | 56% | 61% | 39% | 14% | |
| Net Profit | -32 | 5 | 2 | 23 | 17 | -31 | -125 | -221 | 39 | 18 | 41 | 49 | 41 |
| EPS in Rs | -5.21 | 0.12 | -0.17 | 2.59 | 2.36 | -2.82 | -12.03 | -15.43 | 3.87 | 2.11 | 3.46 | 3.19 | 2.52 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 115.62% | -60.00% | 1050.00% | -26.09% | -282.35% | -303.23% | -76.80% | 117.65% | -53.85% | 127.78% | 19.51% |
| Change in YoY Net Profit Growth (%) | 0.00% | -175.62% | 1110.00% | -1076.09% | -256.27% | -20.87% | 226.43% | 194.45% | -171.49% | 181.62% | -108.27% |
Healthcare Global Enterprises Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | 15% |
| 3 Years: | 17% |
| TTM: | 17% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 52% |
| 5 Years: | 19% |
| 3 Years: | 73% |
| TTM: | -26% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 42% |
| 3 Years: | 37% |
| 1 Year: | 70% |
| Return on Equity | |
|---|---|
| 10 Years: | -1% |
| 5 Years: | 0% |
| 3 Years: | 5% |
| Last Year: | 5% |
Last Updated: September 5, 2025, 5:55 am
Balance Sheet
Last Updated: December 4, 2025, 1:21 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 68 | 70 | 85 | 86 | 87 | 88 | 89 | 125 | 139 | 139 | 139 | 139 | 141 |
| Reserves | 196 | 210 | 341 | 347 | 428 | 389 | 293 | 572 | 731 | 721 | 686 | 783 | 780 |
| Borrowings | 292 | 349 | 324 | 420 | 464 | 658 | 1,347 | 977 | 915 | 901 | 1,274 | 1,837 | 1,768 |
| Other Liabilities | 133 | 147 | 294 | 372 | 461 | 515 | 518 | 357 | 433 | 549 | 601 | 780 | 897 |
| Total Liabilities | 688 | 776 | 1,043 | 1,225 | 1,440 | 1,650 | 2,246 | 2,031 | 2,218 | 2,311 | 2,701 | 3,540 | 3,586 |
| Fixed Assets | 512 | 528 | 583 | 685 | 828 | 970 | 1,646 | 1,382 | 1,547 | 1,553 | 1,758 | 2,442 | 2,430 |
| CWIP | 11 | 42 | 121 | 148 | 174 | 153 | 46 | 30 | 22 | 18 | 83 | 25 | 96 |
| Investments | 2 | 0 | 64 | 11 | 53 | 49 | 34 | 26 | 9 | 10 | 10 | 11 | 13 |
| Other Assets | 164 | 205 | 275 | 381 | 385 | 478 | 520 | 593 | 641 | 730 | 850 | 1,062 | 1,048 |
| Total Assets | 688 | 776 | 1,043 | 1,225 | 1,440 | 1,650 | 2,246 | 2,031 | 2,218 | 2,311 | 2,701 | 3,540 | 3,586 |
Below is a detailed analysis of the balance sheet data for Healthcare Global Enterprises Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 141.00 Cr.. The value appears strong and on an upward trend. It has increased from 139.00 Cr. (Mar 2025) to 141.00 Cr., marking an increase of 2.00 Cr..
- For Reserves, as of Sep 2025, the value is 780.00 Cr.. The value appears to be declining and may need further review. It has decreased from 783.00 Cr. (Mar 2025) to 780.00 Cr., marking a decrease of 3.00 Cr..
- For Borrowings, as of Sep 2025, the value is 1,768.00 Cr.. The value appears to be improving (decreasing). However, Borrowings exceed Reserves, which may signal higher financial risk. It has decreased from 1,837.00 Cr. (Mar 2025) to 1,768.00 Cr., marking a decrease of 69.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 897.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 780.00 Cr. (Mar 2025) to 897.00 Cr., marking an increase of 117.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 3,586.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3,540.00 Cr. (Mar 2025) to 3,586.00 Cr., marking an increase of 46.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 2,430.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2,442.00 Cr. (Mar 2025) to 2,430.00 Cr., marking a decrease of 12.00 Cr..
- For CWIP, as of Sep 2025, the value is 96.00 Cr.. The value appears strong and on an upward trend. It has increased from 25.00 Cr. (Mar 2025) to 96.00 Cr., marking an increase of 71.00 Cr..
- For Investments, as of Sep 2025, the value is 13.00 Cr.. The value appears strong and on an upward trend. It has increased from 11.00 Cr. (Mar 2025) to 13.00 Cr., marking an increase of 2.00 Cr..
- For Other Assets, as of Sep 2025, the value is 1,048.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,062.00 Cr. (Mar 2025) to 1,048.00 Cr., marking a decrease of 14.00 Cr..
- For Total Assets, as of Sep 2025, the value is 3,586.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,540.00 Cr. (Mar 2025) to 3,586.00 Cr., marking an increase of 46.00 Cr..
However, the Borrowings (1,768.00 Cr.) are higher than the Reserves (780.00 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -254.00 | -273.00 | -239.00 | -315.00 | -348.00 | -546.00 | 156.00 | -855.00 | -681.00 | -604.00 | 326.00 | 383.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 43 | 45 | 43 | 54 | 57 | 59 | 62 | 67 | 57 | 65 | 56 | 66 |
| Inventory Days | 33 | 36 | 32 | 40 | 46 | 45 | 35 | 32 | 31 | 33 | 33 | 33 |
| Days Payable | 193 | 208 | 264 | 272 | 274 | 303 | 234 | 221 | 199 | 214 | 216 | 210 |
| Cash Conversion Cycle | -117 | -127 | -188 | -178 | -171 | -200 | -136 | -121 | -112 | -116 | -127 | -111 |
| Working Capital Days | -20 | -65 | -96 | -112 | -74 | -110 | -102 | -26 | -43 | -40 | -70 | -91 |
| ROCE % | 1% | 7% | 6% | 7% | 6% | 3% | 1% | -1% | 5% | 8% | 9% | 9% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Nippon India Small Cap Fund | 4,400,000 | 0.43 | 291.28 | N/A | N/A | N/A |
| Motilal Oswal Multi Cap Fund | 3,500,000 | 5.12 | 231.7 | N/A | N/A | N/A |
| Nippon India ELSS Tax Saver Fund | 3,500,000 | 1.52 | 231.7 | N/A | N/A | N/A |
| Motilal Oswal Business Cycle Fund | 1,750,000 | 5.48 | 115.85 | N/A | N/A | N/A |
| Axis Small Cap Fund | 1,690,271 | 0.42 | 111.9 | N/A | N/A | N/A |
| Axis Flexi Cap Fund | 1,017,366 | 0.52 | 67.35 | N/A | N/A | N/A |
| Tata India Pharma & HealthCare Fund | 958,575 | 4.84 | 63.46 | 939,574 | 2026-01-25 00:34:26 | 2.02% |
| Tata Focused Fund | 828,709 | 2.95 | 54.86 | 758,709 | 2026-01-25 00:34:26 | 9.23% |
| Motilal Oswal Balance Advantage Fund | 750,000 | 5.69 | 49.65 | N/A | N/A | N/A |
| Bandhan Large & Mid Cap Fund | 208,206 | 0.1 | 13.78 | 419,885 | 2026-01-25 00:34:26 | -50.41% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 3.19 | 3.46 | 2.11 | 4.14 | -17.02 |
| Diluted EPS (Rs.) | 3.14 | 3.43 | 2.10 | 3.97 | -17.02 |
| Cash EPS (Rs.) | 18.61 | 15.46 | 13.02 | 14.29 | -4.91 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 66.16 | 59.28 | 61.86 | 63.57 | 56.96 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 66.16 | 59.28 | 61.86 | 63.57 | 56.96 |
| Revenue From Operations / Share (Rs.) | 159.44 | 136.97 | 121.58 | 100.55 | 80.84 |
| PBDIT / Share (Rs.) | 30.28 | 24.88 | 22.42 | 18.03 | 11.45 |
| PBIT / Share (Rs.) | 15.12 | 12.36 | 10.67 | 6.64 | -1.25 |
| PBT / Share (Rs.) | 4.03 | 4.83 | 3.23 | 6.42 | -18.21 |
| Net Profit / Share (Rs.) | 3.45 | 2.94 | 1.27 | 2.90 | -17.61 |
| NP After MI And SOA / Share (Rs.) | 3.19 | 3.46 | 2.11 | 3.87 | -15.43 |
| PBDIT Margin (%) | 18.98 | 18.16 | 18.43 | 17.93 | 14.16 |
| PBIT Margin (%) | 9.48 | 9.02 | 8.77 | 6.60 | -1.54 |
| PBT Margin (%) | 2.52 | 3.52 | 2.65 | 6.38 | -22.52 |
| Net Profit Margin (%) | 2.16 | 2.14 | 1.04 | 2.88 | -21.78 |
| NP After MI And SOA Margin (%) | 1.99 | 2.52 | 1.73 | 3.84 | -19.08 |
| Return on Networth / Equity (%) | 4.81 | 5.83 | 3.41 | 6.17 | -27.74 |
| Return on Capital Employeed (%) | 8.44 | 8.76 | 8.50 | 5.27 | -0.99 |
| Return On Assets (%) | 1.25 | 1.77 | 1.26 | 2.42 | -9.50 |
| Long Term Debt / Equity (X) | 0.65 | 0.58 | 0.42 | 0.41 | 0.49 |
| Total Debt / Equity (X) | 1.09 | 0.81 | 0.46 | 0.46 | 0.59 |
| Asset Turnover Ratio (%) | 0.71 | 0.75 | 0.74 | 0.46 | 0.31 |
| Current Ratio (X) | 0.80 | 0.91 | 1.02 | 1.07 | 0.93 |
| Quick Ratio (X) | 0.75 | 0.85 | 0.95 | 1.01 | 0.88 |
| Inventory Turnover Ratio (X) | 46.46 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 2.73 | 3.19 | 3.01 | 2.56 | 1.20 |
| Interest Coverage Ratio (Post Tax) (X) | 1.31 | 1.34 | 1.17 | 0.44 | -0.06 |
| Enterprise Value (Cr.) | 8223.42 | 5119.81 | 3866.17 | 3975.48 | 2784.14 |
| EV / Net Operating Revenue (X) | 3.70 | 2.68 | 2.29 | 2.84 | 2.75 |
| EV / EBITDA (X) | 19.48 | 14.77 | 12.40 | 15.86 | 19.40 |
| MarketCap / Net Operating Revenue (X) | 3.37 | 2.47 | 2.16 | 2.68 | 2.36 |
| Price / BV (X) | 8.13 | 5.70 | 4.25 | 4.31 | 3.44 |
| Price / Net Operating Revenue (X) | 3.37 | 2.47 | 2.16 | 2.68 | 2.36 |
| EarningsYield | 0.01 | 0.01 | 0.01 | 0.01 | -0.08 |
After reviewing the key financial ratios for Healthcare Global Enterprises Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 3.19. This value is below the healthy minimum of 5. It has decreased from 3.46 (Mar 24) to 3.19, marking a decrease of 0.27.
- For Diluted EPS (Rs.), as of Mar 25, the value is 3.14. This value is below the healthy minimum of 5. It has decreased from 3.43 (Mar 24) to 3.14, marking a decrease of 0.29.
- For Cash EPS (Rs.), as of Mar 25, the value is 18.61. This value is within the healthy range. It has increased from 15.46 (Mar 24) to 18.61, marking an increase of 3.15.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 66.16. It has increased from 59.28 (Mar 24) to 66.16, marking an increase of 6.88.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 66.16. It has increased from 59.28 (Mar 24) to 66.16, marking an increase of 6.88.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 159.44. It has increased from 136.97 (Mar 24) to 159.44, marking an increase of 22.47.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 30.28. This value is within the healthy range. It has increased from 24.88 (Mar 24) to 30.28, marking an increase of 5.40.
- For PBIT / Share (Rs.), as of Mar 25, the value is 15.12. This value is within the healthy range. It has increased from 12.36 (Mar 24) to 15.12, marking an increase of 2.76.
- For PBT / Share (Rs.), as of Mar 25, the value is 4.03. This value is within the healthy range. It has decreased from 4.83 (Mar 24) to 4.03, marking a decrease of 0.80.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 3.45. This value is within the healthy range. It has increased from 2.94 (Mar 24) to 3.45, marking an increase of 0.51.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 3.19. This value is within the healthy range. It has decreased from 3.46 (Mar 24) to 3.19, marking a decrease of 0.27.
- For PBDIT Margin (%), as of Mar 25, the value is 18.98. This value is within the healthy range. It has increased from 18.16 (Mar 24) to 18.98, marking an increase of 0.82.
- For PBIT Margin (%), as of Mar 25, the value is 9.48. This value is below the healthy minimum of 10. It has increased from 9.02 (Mar 24) to 9.48, marking an increase of 0.46.
- For PBT Margin (%), as of Mar 25, the value is 2.52. This value is below the healthy minimum of 10. It has decreased from 3.52 (Mar 24) to 2.52, marking a decrease of 1.00.
- For Net Profit Margin (%), as of Mar 25, the value is 2.16. This value is below the healthy minimum of 5. It has increased from 2.14 (Mar 24) to 2.16, marking an increase of 0.02.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 1.99. This value is below the healthy minimum of 8. It has decreased from 2.52 (Mar 24) to 1.99, marking a decrease of 0.53.
- For Return on Networth / Equity (%), as of Mar 25, the value is 4.81. This value is below the healthy minimum of 15. It has decreased from 5.83 (Mar 24) to 4.81, marking a decrease of 1.02.
- For Return on Capital Employeed (%), as of Mar 25, the value is 8.44. This value is below the healthy minimum of 10. It has decreased from 8.76 (Mar 24) to 8.44, marking a decrease of 0.32.
- For Return On Assets (%), as of Mar 25, the value is 1.25. This value is below the healthy minimum of 5. It has decreased from 1.77 (Mar 24) to 1.25, marking a decrease of 0.52.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.65. This value is within the healthy range. It has increased from 0.58 (Mar 24) to 0.65, marking an increase of 0.07.
- For Total Debt / Equity (X), as of Mar 25, the value is 1.09. This value exceeds the healthy maximum of 1. It has increased from 0.81 (Mar 24) to 1.09, marking an increase of 0.28.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.71. It has decreased from 0.75 (Mar 24) to 0.71, marking a decrease of 0.04.
- For Current Ratio (X), as of Mar 25, the value is 0.80. This value is below the healthy minimum of 1.5. It has decreased from 0.91 (Mar 24) to 0.80, marking a decrease of 0.11.
- For Quick Ratio (X), as of Mar 25, the value is 0.75. This value is below the healthy minimum of 1. It has decreased from 0.85 (Mar 24) to 0.75, marking a decrease of 0.10.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 46.46. This value exceeds the healthy maximum of 8. It has increased from 0.00 (Mar 24) to 46.46, marking an increase of 46.46.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 2.73. This value is below the healthy minimum of 3. It has decreased from 3.19 (Mar 24) to 2.73, marking a decrease of 0.46.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.31. This value is below the healthy minimum of 3. It has decreased from 1.34 (Mar 24) to 1.31, marking a decrease of 0.03.
- For Enterprise Value (Cr.), as of Mar 25, the value is 8,223.42. It has increased from 5,119.81 (Mar 24) to 8,223.42, marking an increase of 3,103.61.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.70. This value exceeds the healthy maximum of 3. It has increased from 2.68 (Mar 24) to 3.70, marking an increase of 1.02.
- For EV / EBITDA (X), as of Mar 25, the value is 19.48. This value exceeds the healthy maximum of 15. It has increased from 14.77 (Mar 24) to 19.48, marking an increase of 4.71.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 3.37. This value exceeds the healthy maximum of 3. It has increased from 2.47 (Mar 24) to 3.37, marking an increase of 0.90.
- For Price / BV (X), as of Mar 25, the value is 8.13. This value exceeds the healthy maximum of 3. It has increased from 5.70 (Mar 24) to 8.13, marking an increase of 2.43.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 3.37. This value exceeds the healthy maximum of 3. It has increased from 2.47 (Mar 24) to 3.37, marking an increase of 0.90.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Healthcare Global Enterprises Ltd:
- Net Profit Margin: 2.16%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 8.44% (Industry Average ROCE: 15.48%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 4.81% (Industry Average ROE: 14.81%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.31
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.75
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 295 (Industry average Stock P/E: 87.63)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 1.09
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 2.16%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Hospitals & Medical Services | HCG Tower, Bengaluru Karnataka 560027 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Dr. B S Ajai Kumar | Executive Chairman |
| Dr. Manish Mattoo | Executive Director & CEO |
| Ms. Anjali Ajaikumar | Non Exe.Non Ind.Director |
| Mr. Akshay Tanna | Non Exe.Non Ind.Director |
| Ms. Simrun Mehta | Non Exe.Non Ind.Director |
| Ms. Geeta Mathur | Ind. Non-Executive Director |
| Mr. Pradip Kanakia | Ind. Non-Executive Director |
| Mr. Rajiv Maliwal | Ind. Non-Executive Director |
| Mr. Raj Raghavan | Ind. Non-Executive Director |
| Mr. Bijou Kurien | Ind. Non-Executive Director |
FAQ
What is the intrinsic value of Healthcare Global Enterprises Ltd?
Healthcare Global Enterprises Ltd's intrinsic value (as of 06 February 2026) is ₹741.53 which is 30.32% higher the current market price of ₹569.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹8,022 Cr. market cap, FY2025-2026 high/low of ₹805/473, reserves of ₹780 Cr, and liabilities of ₹3,586 Cr.
What is the Market Cap of Healthcare Global Enterprises Ltd?
The Market Cap of Healthcare Global Enterprises Ltd is 8,022 Cr..
What is the current Stock Price of Healthcare Global Enterprises Ltd as on 06 February 2026?
The current stock price of Healthcare Global Enterprises Ltd as on 06 February 2026 is ₹569.
What is the High / Low of Healthcare Global Enterprises Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Healthcare Global Enterprises Ltd stocks is ₹805/473.
What is the Stock P/E of Healthcare Global Enterprises Ltd?
The Stock P/E of Healthcare Global Enterprises Ltd is 295.
What is the Book Value of Healthcare Global Enterprises Ltd?
The Book Value of Healthcare Global Enterprises Ltd is 65.3.
What is the Dividend Yield of Healthcare Global Enterprises Ltd?
The Dividend Yield of Healthcare Global Enterprises Ltd is 0.00 %.
What is the ROCE of Healthcare Global Enterprises Ltd?
The ROCE of Healthcare Global Enterprises Ltd is 8.56 %.
What is the ROE of Healthcare Global Enterprises Ltd?
The ROE of Healthcare Global Enterprises Ltd is 5.14 %.
What is the Face Value of Healthcare Global Enterprises Ltd?
The Face Value of Healthcare Global Enterprises Ltd is 10.0.